Suscetibilidade in vitro de Conidiobolus lamprauges frente a fármacos antimicrobianos

Detalhes bibliográficos
Autor(a) principal: Stefanello, Josias da Rosa
Data de Publicação: 2018
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Manancial - Repositório Digital da UFSM
dARK ID: ark:/26339/001300000dd9b
Texto Completo: http://repositorio.ufsm.br/handle/1/18722
Resumo: Conidiobolomycosis is an important and difficult-to-treat infection. The disease is caused by the fungi Conidiobolus coronatus, C. incongruus and C. lamprauges, affecting sheep, horses, dogs and humans. There is no common understanding about the ideal antifungal therapy for the infection treatment. Assessment of antifungal susceptibility is one way of monitoring resistance and predicting appropriate therapies. Therefore, the present study assessed the sensibility of seven isolates of C. lamprauges considering the antifungal drugs Amphotericin B, voriconazole, miconazole and terbinafine, the antibacterial drugs sulfamethoxazole + trimethoprim, azithromycin and dapsone and the antiprotozoal drug miltefosine, in an isolated an in association manner, through the checkerboard method, by means of the broth microdilution method, which is standardized by the M38-A2 document, of the Clinical and Laboratory Standards Institute (CLSI). In an isolated way, the minimum inhibitory concentrations (MICs), for Amphotericin B, vary in 0.25-1.0 μg/mL, to miconazole 2.0-8.0 μg/mL, to terbinafine 0.25-2.0 μg/mL, to voriconazole 512 μg/mL, to sulfamethoxazole + trimethoprim, 32/6.4-256/51.2 μg/mL, azithromycin >64, to dapsone >32 μg/mL and to miltefosine 2-16 μg/mL. Higher rates of synergism were observed in the combinations of miltefosine + azithromycin (100%), miltefosine + dapsone (100%), azithromycin + dapsone (85.7%). The most relevant associations deserve attention as candidates for Conidiobolus spp. infection treatment. Hence, further in vitro and in vivo studies with a wide range of clinical isolates and different Conidiobolus spp. are needed to better understand the susceptibility to the antimicrobials described in this study.
id UFSM_5928bbcb09a0ae1accefdc558df1a4ec
oai_identifier_str oai:repositorio.ufsm.br:1/18722
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Suscetibilidade in vitro de Conidiobolus lamprauges frente a fármacos antimicrobianosIn vitro suscetibility of Conidiobolus lamprauges against antimicrobial drugsConidiobolomicoseTeste de suscetibilidadeTerbinafinaDapsonaMiltefosinaConidiobolomycosisSusceptibilityTestingTerbinafineCNPQ::CIENCIAS DA SAUDE::FARMACIAConidiobolomycosis is an important and difficult-to-treat infection. The disease is caused by the fungi Conidiobolus coronatus, C. incongruus and C. lamprauges, affecting sheep, horses, dogs and humans. There is no common understanding about the ideal antifungal therapy for the infection treatment. Assessment of antifungal susceptibility is one way of monitoring resistance and predicting appropriate therapies. Therefore, the present study assessed the sensibility of seven isolates of C. lamprauges considering the antifungal drugs Amphotericin B, voriconazole, miconazole and terbinafine, the antibacterial drugs sulfamethoxazole + trimethoprim, azithromycin and dapsone and the antiprotozoal drug miltefosine, in an isolated an in association manner, through the checkerboard method, by means of the broth microdilution method, which is standardized by the M38-A2 document, of the Clinical and Laboratory Standards Institute (CLSI). In an isolated way, the minimum inhibitory concentrations (MICs), for Amphotericin B, vary in 0.25-1.0 μg/mL, to miconazole 2.0-8.0 μg/mL, to terbinafine 0.25-2.0 μg/mL, to voriconazole 512 μg/mL, to sulfamethoxazole + trimethoprim, 32/6.4-256/51.2 μg/mL, azithromycin >64, to dapsone >32 μg/mL and to miltefosine 2-16 μg/mL. Higher rates of synergism were observed in the combinations of miltefosine + azithromycin (100%), miltefosine + dapsone (100%), azithromycin + dapsone (85.7%). The most relevant associations deserve attention as candidates for Conidiobolus spp. infection treatment. Hence, further in vitro and in vivo studies with a wide range of clinical isolates and different Conidiobolus spp. are needed to better understand the susceptibility to the antimicrobials described in this study.A conidiobolomicose é uma infecção importante, de difícil tratamento. A doença é causada pelos fungos Conidiobolus coronatus, C. incongruus e C. lamprauges, afetando ovinos, equinos, caninos e humanos. Não há um consenso sobre a terapia antifúngica ideal para o tratamento da infecção. A avaliação da suscetibilidade aos antifúngicos é uma forma de monitorar a resistência e optar por terapias com melhor resposta. Nesse intuito, o presente estudo avaliou a sensibilidade de sete isolados de C. lamprauges frente aos fármacos antifúngicos anfotericina B, voriconazol, miconazol e terbinafina, aos fármacos antibacterianos, sulfametoxazol+trimetoprima, azitromicina e dapsona, e ao fármaco antiprotozoário, miltefosina, de forma isolada e em associação, por meio do método de “checkerboard”, baseado na metodologia de microdiluição em caldo padronizada pelo documento M38-A2 do Clinical and Laboratory Standards Institute (CLSI). Isoladamente, as concentrações inibitórias mínimas (CIMs) para anfotericina B, variaram de 0,25-1,0 μg/mL, para o miconazol 2,0-8,0 μg/mL, para a terbinafina 0,25-2,0 μg/mL, para o voriconazol 512 μg/mL, para sulfametoxazol+trimetoprima, 32/6,4-256/51,2 μg/mL, azitromicina >64, para a dapsona >32 μg/mL e para miltefosina 2-16 μg/mL. Altas taxas de sinergismo foram observadas nas combinações de miltefosina + azitromicina (100%), miltefosina + dapsona (100%), azitromicina + dapsona (85,7%). As associações de maior relevância merecem atenção como candidatas para o tratamento de infecções por Conidiobolus spp.. Assim sendo, estudos adicionais in vitro e in vivo com uma ampla gama de isolados clínicos e diferentes Conidiobolus spp. são necessários para entender melhor a suscetibilidade aos antimicrobianos descritos neste estudo.Universidade Federal de Santa MariaBrasilFarmacologiaUFSMPrograma de Pós-Graduação em FarmacologiaCentro de Ciências da SaúdeSanturio, Janio Moraishttp://lattes.cnpq.br/6316012260769979Loreto, Érico Silva dehttp://lattes.cnpq.br/5475233864057995Botton, Sônia de Avilahttp://lattes.cnpq.br/0814772095155945Stefanello, Josias da Rosa2019-10-30T22:04:20Z2019-10-30T22:04:20Z2018-08-23info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://repositorio.ufsm.br/handle/1/18722ark:/26339/001300000dd9bporAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2019-10-31T06:01:35Zoai:repositorio.ufsm.br:1/18722Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/ONGhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.comopendoar:2019-10-31T06:01:35Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Suscetibilidade in vitro de Conidiobolus lamprauges frente a fármacos antimicrobianos
In vitro suscetibility of Conidiobolus lamprauges against antimicrobial drugs
title Suscetibilidade in vitro de Conidiobolus lamprauges frente a fármacos antimicrobianos
spellingShingle Suscetibilidade in vitro de Conidiobolus lamprauges frente a fármacos antimicrobianos
Stefanello, Josias da Rosa
Conidiobolomicose
Teste de suscetibilidade
Terbinafina
Dapsona
Miltefosina
Conidiobolomycosis
Susceptibility
Testing
Terbinafine
CNPQ::CIENCIAS DA SAUDE::FARMACIA
title_short Suscetibilidade in vitro de Conidiobolus lamprauges frente a fármacos antimicrobianos
title_full Suscetibilidade in vitro de Conidiobolus lamprauges frente a fármacos antimicrobianos
title_fullStr Suscetibilidade in vitro de Conidiobolus lamprauges frente a fármacos antimicrobianos
title_full_unstemmed Suscetibilidade in vitro de Conidiobolus lamprauges frente a fármacos antimicrobianos
title_sort Suscetibilidade in vitro de Conidiobolus lamprauges frente a fármacos antimicrobianos
author Stefanello, Josias da Rosa
author_facet Stefanello, Josias da Rosa
author_role author
dc.contributor.none.fl_str_mv Santurio, Janio Morais
http://lattes.cnpq.br/6316012260769979
Loreto, Érico Silva de
http://lattes.cnpq.br/5475233864057995
Botton, Sônia de Avila
http://lattes.cnpq.br/0814772095155945
dc.contributor.author.fl_str_mv Stefanello, Josias da Rosa
dc.subject.por.fl_str_mv Conidiobolomicose
Teste de suscetibilidade
Terbinafina
Dapsona
Miltefosina
Conidiobolomycosis
Susceptibility
Testing
Terbinafine
CNPQ::CIENCIAS DA SAUDE::FARMACIA
topic Conidiobolomicose
Teste de suscetibilidade
Terbinafina
Dapsona
Miltefosina
Conidiobolomycosis
Susceptibility
Testing
Terbinafine
CNPQ::CIENCIAS DA SAUDE::FARMACIA
description Conidiobolomycosis is an important and difficult-to-treat infection. The disease is caused by the fungi Conidiobolus coronatus, C. incongruus and C. lamprauges, affecting sheep, horses, dogs and humans. There is no common understanding about the ideal antifungal therapy for the infection treatment. Assessment of antifungal susceptibility is one way of monitoring resistance and predicting appropriate therapies. Therefore, the present study assessed the sensibility of seven isolates of C. lamprauges considering the antifungal drugs Amphotericin B, voriconazole, miconazole and terbinafine, the antibacterial drugs sulfamethoxazole + trimethoprim, azithromycin and dapsone and the antiprotozoal drug miltefosine, in an isolated an in association manner, through the checkerboard method, by means of the broth microdilution method, which is standardized by the M38-A2 document, of the Clinical and Laboratory Standards Institute (CLSI). In an isolated way, the minimum inhibitory concentrations (MICs), for Amphotericin B, vary in 0.25-1.0 μg/mL, to miconazole 2.0-8.0 μg/mL, to terbinafine 0.25-2.0 μg/mL, to voriconazole 512 μg/mL, to sulfamethoxazole + trimethoprim, 32/6.4-256/51.2 μg/mL, azithromycin >64, to dapsone >32 μg/mL and to miltefosine 2-16 μg/mL. Higher rates of synergism were observed in the combinations of miltefosine + azithromycin (100%), miltefosine + dapsone (100%), azithromycin + dapsone (85.7%). The most relevant associations deserve attention as candidates for Conidiobolus spp. infection treatment. Hence, further in vitro and in vivo studies with a wide range of clinical isolates and different Conidiobolus spp. are needed to better understand the susceptibility to the antimicrobials described in this study.
publishDate 2018
dc.date.none.fl_str_mv 2018-08-23
2019-10-30T22:04:20Z
2019-10-30T22:04:20Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufsm.br/handle/1/18722
dc.identifier.dark.fl_str_mv ark:/26339/001300000dd9b
url http://repositorio.ufsm.br/handle/1/18722
identifier_str_mv ark:/26339/001300000dd9b
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
Centro de Ciências da Saúde
publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Farmacologia
UFSM
Programa de Pós-Graduação em Farmacologia
Centro de Ciências da Saúde
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com
_version_ 1815172326904299520